Chin Med J (Taipei) 1996;58:264-8.

[ Next ] [ Prev ] [ Chi ] [ TOC ] [ Home ]

An Add-On Study of Selegiline to Madopar in the Treatment of Parkinsonian Patients With Dose-Related Fluctuations: Comparison Between Jumexal and Parkryl

Din-E Shan, Shyh-Ing Yeh

Neurology, Neurological Institute, Veterans General Hospital-Taipei; and Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

Abstract

Background. To improve dose-related fluctuations in patients with Parkinson's disease, the efficacy of selegiline, a selective inhibitor of monoamine oxidase B, was determined.

Methods. Twenty parkinsonian patients were selected for a short-term, single-blind, cross-over trial. Each patient received one of the two brands of selegiline, Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar. After a 6-week treatment period and a 4-week wash-out period, the treatment was switched to the other brand of selegiline, Jumexal (Labatec), for another 6 weeks.

Results. Five patients dropped out of the study because of the development of intolerable dyskinesia, hallucination or agitation. The 15 patients that completed the study made a mild improvement in the total motor scores of the on-period during both treatments of Parkryl (p < 0.01) and of Jumexal (p < 0.05). The recorded daily off-time decreased from 37.8% to 20.7% in the Parkryl group (p < 0.01), and to 21.0% in the Jumexal group (p < 0.01).

Conclusions. Selegiline, as an adjunct therapy to Madopar, has a moderate effect in prolonging the duration of on-time in parkinsonian patients with dose-related fluctuations. Jumexal seemed to produce no greater effect than Parkryl.

[Chin Med J (Taipei) 1996;58:264-8.]

Keywords: motor fluctuation, Parkinson's disease, selegiline

Received: March 27, 1996.

Accepted: June 6, 1996.

Reprint requests to:

Din-E Shan, M.D., Ph.D.
Neurological Institute
Veterans General Hospital-Taipei
No. 201, Sec. 2, Shih-Pai Road
Taipei, Taiwan, R.O.C.